Oral cholera vaccines: use in clinical practice.

Authors:
Address: National Travel Health Network and Centre, London, UK. david.hill@uclh.org
Journal:

Publication:

abstract

cholera continues to occur globally, particularly in sub-Saharan Africa and Asia. Oral cholera vaccines have been developed and have now been used for several years, primarily in traveller populations. The licensure in the European Union of a killed whole cell cholera vaccine combined with the recombinant B subunit of cholera toxin (rCTB-WC) has stimulated interest in protection against cholera. Because of the similarity between cholera toxin and the heat-labile toxin of Escherichia coli, a cause of travellers' diarrhoea, it has been proposed that the rCTB-WC vaccine may be used against travellers' diarrhoea. An analysis of trials of this vaccine against cholera (serotype O1) shows that for 4-6 months it will protect 61-86% of people living in cholera-endemic regions; lower levels of protection continue for 3 years. Protection wanes rapidly in young children. Because the risk of cholera for most travellers is extremely low, vaccination should be considered only for those working in relief or refugee settings or for those who will be travelling in cholera-epidemic areas and who will be unable to obtain prompt medical care. The vaccine can be expected to prevent 7% or less of cases of travellers' diarrhoea and should not be used for this purpose.

Related Articles
Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.
Vaccine. 2005
Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.
Leyten EM, Soonawala D, Schultsz C, Herzog C, Ligthelm RJ, Wijnands S, Visser LG. Vaccine. 2005 Oct 17; 23(43):5120-6.
Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS.
Travel Med Infect Dis. 2007
Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS.
López-Gigosos R, García-Fortea P, Reina-Doña E, Plaza-Martín E. Travel Med Infect Dis. 2007 Nov; 5(6):380-4. Epub 2007 Jul 30.
Reduction of travellers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers.
Vaccine. 2009
Reduction of travellers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers.
Torrell JM, Aumatell CM, Ramos SM, Mestre LG, Salas CM. Vaccine. 2009 Jun 19; 27(30):4074-7. Epub 2009 May 3.
Review Cholera vaccines.
Clin Infect Dis. 2000
Review Cholera vaccines.
Ryan ET, Calderwood SB. Clin Infect Dis. 2000 Aug; 31(2):561-5. Epub 2000 Sep 7.
Review A review of the current status of enteric vaccines.
P N G Med J. 1995
Review A review of the current status of enteric vaccines.
Levine MM, Noriega F. P N G Med J. 1995 Dec; 38(4):325-31.
Review of oral cholera vaccines: efficacy in young children.
Infect Drug Resist. 2011
Review of oral cholera vaccines: efficacy in young children.
Masuet Aumatell C, Ramon Torrell JM, Zuckerman JN. Infect Drug Resist. 2011; 4:155-60. Epub 2011 Sep 14.
Development of vaccines against burkholderia pseudomallei.
Front Microbiol. 2011
Development of vaccines against burkholderia pseudomallei.
Patel N, Conejero L, De Reynal M, Easton A, Bancroft GJ, Titball RW. Front Microbiol. 2011; 2:198. Epub 2011 Sep 27.
Vaccination strategies to combat an infectious globe: oral cholera vaccines.
J Glob Infect Dis. 2011
Vaccination strategies to combat an infectious globe: oral cholera vaccines.
López-Gigosos RM, Plaza E, Díez-Díaz RM, Calvo MJ. J Glob Infect Dis. 2011 Jan; 3(1):56-62.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.